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SARS-CoV-2 antibody tests of varying specificity and sensitivity are now available. For 
informing individuals whether they have had COVID-19, they need to be very accurate. For 
measuring population prevalence of past infection, the numbers of false positives and negatives 
need to be roughly equal.  
With a series of worked examples for a notional population of 100,000 people, we show that 
even test systems with a high specificity can yield a large number of false positive results, 
especially where the population prevalence is low. For example, at a true population prevalence 
of 5%, using a test with 99% sensitivity and specificity, 16% of positive results will be false and 
thus 950 people will be incorrectly informed they have had the infection. Further confirmatory 
testing may be needed.  
Giving false reassurance upon which personal or societal decisions might be based could be 
harmful for individuals, undermine public confidence and foster further outbreaks.   
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• COVID-19 antibody tests need to be very reliable to inform individual decisions 
• Even with high specificity, antibody tests can produce many false positives 
• Giving false reassurance could undermine public confidence and foster new outbreaks 
 
 
Main text  
 
To help reverse the current lockdowns while suppressing COVID-19 rates, we need to identify 
who currently has the infection and who has had it and recovered. As RT-PCR testing to detect 
current infection has been recently discussed in detail,1 we focus in this paper on antibody tests. 
The presence or absence of antibodies can inform individuals if they have had the infection or 
not and guide personal and societal decisions about if and when they can return to normal 
activities. Antibody testing thus needs to be particularly accurate. It can also be used to provide 
an estimate of the population prevalence of previous infection. We demonstrate that for this 
purpose high accuracy is not required, but the numbers of false positives and false negatives need 
to be approximately equal. 
 
Antibody tests are increasingly available but with variable accuracy. It is hoped they can be used 
to identify people who are at least partially immune. Immunity certificates, a more appropriate 
phrase than immunity passports that promises too much, for individuals thought to have 
recovered from COVID-19, are being discussed internationally.2 3 4 Whether tests are done for 
clinical diagnosis, screening or immunity certificates, we need to have sufficient confidence they 
are accurate.  
  
A sensitive test will detect the presence of antibodies to SARS-CoV-2 (the virus that causes 
COVID-19), and a specific test will not react to other antibodies e.g. to other coronaviruses. No 
diagnostic or screening test is perfect and incorrect results are inevitable, not least because the 
timing of the test is critical. Seroconversion takes time, with IgM, IgG and IgA antibodies 
usually developing in that order, and can be variable and dependent upon the severity of the 
illness and the individual’s immune system. Antibody levels subsequently decline with time. 
Antibody test systems may perform less well than the manufacturers’ results suggest. For 
example, both Roche and Abbott reported their antibody test had 100% sensitivity for samples 
taken 14 days or more after the onset of symptoms, yet Public Health England found sensitivity 
at 14 or more days of only 87% and 93.4% respectively.5 6 
 
We show here how to measure the test’s accuracy and how this changes along with the 
prevalence of disease (12 tables showing the results with varying sensitivity, specificity and 
population prevalence of 1%, 5%, 10%, and 20% are available in the Supplementary File). The 
two key measures of its accuracy are sensitivity and specificity, set out in Table 1, with the cells 
identified as A (true positives), B (false positives), C (false negatives), and D (true negatives). 
Sensitivity (A/A+C) is the proportion of people with a disease who, when tested, receive a 
positive test result. It is also known as the true positive rate. Specificity (D/D+B) is the 
proportion of individuals without a disease who, when tested, receive a negative test result. It is 
also known as the true negative rate.  
 
To establish sensitivity and specificity, we could test a sample of patients with proven disease (in 
this case laboratory detection of SARS-CoV-2), and a sample of people known to be free of 
disease (for example, using stored blood samples taken before COVID-19 existed in humans). In 
practice, a test’s performance will usually be poorer than the values established due, for example, 
to problems in storing or transporting specimens or the variable time lag from the onset of 
infection until antibodies appear in the blood (seroconversion) and then decline. The proportion 
of test results that are false partly depends on the prevalence of the disease in the population. 
With a low prevalence, even a test with high sensitivity and specificity will produce a high 
proportion of false positives. In this paper, we focus on the outcomes of tests of variable 
accuracy with 5% population prevalence in a hypothetical group of 100,000 people, of whom 
5,000 have had the infection and 95,000 have not. This is a plausible current prevalence of past 
COVID-19 in many countries7 8 9 although it could be a lot higher in some areas.  
 
Table 1 shows that if the sensitivity is 90%, 4,500 people will correctly test positive, but 500 will 
incorrectly test negative and be wrongly told they have no antibody evidence of the disease. If 
the specificity is 90%, 85,500 people will correctly test negative, but 9,500 will incorrectly test 
positive and be wrongly told they have antibody evidence of previous infection Thus, of the 
14,000 people who received positive test results, only 32% (4,500/14,000; A/A+B) had the 
disease. This is referred to as the predictive value (or power) of a positive test. The other 68% 
would be given wrong information. Of the 86,000 people who received negative tests, 99% 
(85,500/86,000; D/C+D) would receive a correct result. This is called the predictive value (or 
power) of a negative test.  
 
Sensitivity and specificity vary with different tests but, for any particular antibody test, these can 
be adjusted by altering the level of antibody required to determine a positive result. Requiring a 
higher level of antibody for a positive result would increase the specificity but lower the 
sensitivity. This would reduce the false positives (C) but increase the false negatives (B). 
Choosing a test that has 80% sensitivity and 99% specificity, as shown in Table 2, 81% of people 
who test positive have had the disease, an increase from 32%. Now, about one in five people 
who test positive will not have had the disease. This shows that when the prevalence of the 
disease is low, antibody testing, even with a specificity as high as 99%, still produces many false 
positives so the predictive power of a positive test is far from 100%. 
 
If a test is extremely accurate, as is claimed for the Roche and Abbott systems, say 99% 
sensitivity and specificity, the results are shown in table 3. Even now, the predictive power of a 
positive test has only risen from 81% with a sensitivity of 90%, to 83.8%. If the prevalence rises 
to 20% then the predictive power of a positive test is 96.1% and of a negative test 99.7% 
(Supplementary File Table A12). 
 
If immunity certificates, or personal or societal decisions about returning to normality, are based 
on these results, a significant proportion will be incorrect. Where the disease has become highly 
prevalent, for example among health care and care home workers, the power of a positive test 
would be higher, so more reliance could be placed on it. Even with a prevalence of 20% and 99% 
sensitivity and specificity the test itself does not give a guarantee at the individual level and 
personal and clinical judgements are required in applying the findings. A major hope of antibody 
testing is that those who test positive can resume work and social activities more fully and 
confidently than those who test negative. The presence of antibodies should signify the same 
illness will not recur, the person is not contagious and there is at least partial immunity to future 
COVID-19 infections. We need to establish whether this is true.10  
If the purpose of antibody testing is to assess the prevalence of COVID-19 in a representative 
sample of the population, these clinical issues do not apply. The veracity of the prevalence 
derived by such measurements will depend upon achieving equal false positives and false 
negatives. For example, while the true prevalence is 5%, Tables 1, 2 and 3 give a prevalence in 
the hypothetical population of 100,000 people of 14% (14,000 positives), 4.95% (4,950 
positives) and 5.9% (5,900 positives) respectively. Perhaps surprisingly, the test with 80% 
sensitivity and 99% specificity (Table 2) gives the most accurate estimate at this level of 
population prevalence. 
 
In conclusion, at currently reasonable estimates of general population prevalence, even high 
sensitivity and specificity will produce an important number of false positives. People testing 
positive, especially those without indicative case histories, may need further testing to confirm 
the result. Given the current uncertainty about the level of immunity signalled by antibodies, all 
those testing positive for antibodies would be well advised to maintain protective measures. 
More information is also urgently needed to ascertain the strength and duration of immunity in 
people who have recovered from COVID-19 and whether some can still be infectious or become 
re-infected. Giving false security and reassurance could be harmful for individuals, undermine 
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Table 1 Predictive powers of a test with 90% sensitivity and specificity (5% prevalence) 
Test result (90% 
sensitivity and 
90% specificity) 
People truly with 
disease 
People truly without 
disease 
Totals 
    
Positive 4,500 (A) 9,500 (B) 14,000 
Negative 500 (C) 85,500 (D) 86,000 
Total 5,000 95,000 100,000 
Predictive value of a positive test: A/A+B = 32.1% 




Table 2 Predictive powers of a test with 80% sensitivity and 99% specificity (5% prevalence) 
Test result (80% 
sensitivity and 
99% specificity) 
People truly with 
disease 
People truly without 
disease 
Totals 
    
Positive 4,000 (A) 950 (B) 4,950 
Negative 1,000 (C) 94,050 (D) 95,050 
Total 5,000 95,000 100,000 
Predictive value of a positive test: A/A+B = 80.8%  
Predictive value of a negative test: D/D+C = 98.9% 
 
 
Table 3 Predictive powers of a test with 99% sensitivity and 99% specificity (5% prevalence) 
Test result (99% 
sensitivity and 
99% specificity) 
People truly with 
disease 
People truly without 
disease 
Totals 
    
Positive 4,950 (A) 950 (B) 5,900 
Negative 50 (C) 94,050 (D) 94,100 
Total 5,000 95,000  100,000 
Predictive value of a positive test: A/A+B = 83.8% 
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